Privia Health Group, Inc. (NASDAQ:PRVA) Shares Purchased by WCM Investment Management LLC

WCM Investment Management LLC raised its holdings in Privia Health Group, Inc. (NASDAQ:PRVA) by 9.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 549,087 shares of the company’s stock after acquiring an additional 46,556 shares during the quarter. WCM Investment Management LLC owned 0.47% of Privia Health Group worth $13,145,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in the stock. Tower Research Capital LLC TRC lifted its stake in shares of Privia Health Group by 171.1% in the first quarter. Tower Research Capital LLC TRC now owns 1,578 shares of the company’s stock valued at $44,000 after purchasing an additional 996 shares during the period. Point72 Hong Kong Ltd acquired a new stake in shares of Privia Health Group during the 1st quarter valued at approximately $47,000. Neo Ivy Capital Management purchased a new stake in shares of Privia Health Group during the 2nd quarter worth approximately $53,000. Benjamin Edwards Inc. acquired a new stake in shares of Privia Health Group in the 2nd quarter worth approximately $58,000. Finally, Jefferies Financial Group Inc. acquired a new stake in shares of Privia Health Group in the 4th quarter worth approximately $72,000. 94.48% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CFO David Mountcastle sold 3,933 shares of the company’s stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $17.77, for a total value of $69,889.41. Following the completion of the sale, the chief financial officer now owns 262,279 shares in the company, valued at approximately $4,660,697.83. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, CFO David Mountcastle sold 3,933 shares of the stock in a transaction dated Tuesday, April 2nd. The stock was sold at an average price of $17.77, for a total value of $69,889.41. Following the completion of the sale, the chief financial officer now directly owns 262,279 shares of the company’s stock, valued at approximately $4,660,697.83. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director William M. Sullivan sold 9,951 shares of Privia Health Group stock in a transaction dated Wednesday, January 24th. The shares were sold at an average price of $23.03, for a total value of $229,171.53. Following the transaction, the director now directly owns 5,464,533 shares in the company, valued at approximately $125,848,194.99. The disclosure for this sale can be found here. Corporate insiders own 57.60% of the company’s stock.

Privia Health Group Price Performance

NASDAQ:PRVA traded up $0.20 during mid-day trading on Friday, reaching $18.54. The company’s stock had a trading volume of 759,055 shares, compared to its average volume of 778,585. Privia Health Group, Inc. has a twelve month low of $17.54 and a twelve month high of $30.15. The company’s fifty day simple moving average is $20.31 and its two-hundred day simple moving average is $21.56. The stock has a market cap of $2.20 billion, a P/E ratio of 97.58, a P/E/G ratio of 2.53 and a beta of 0.81.

Privia Health Group (NASDAQ:PRVA) last issued its earnings results on Tuesday, February 27th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). Privia Health Group had a return on equity of 3.97% and a net margin of 1.39%. The company had revenue of $440.80 million during the quarter, compared to analyst estimates of $425.81 million. During the same quarter in the previous year, the firm earned $0.14 earnings per share. The business’s revenue was up 21.0% compared to the same quarter last year. Sell-side analysts expect that Privia Health Group, Inc. will post 0.26 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have commented on the company. Canaccord Genuity Group decreased their target price on Privia Health Group from $41.00 to $37.00 and set a “buy” rating on the stock in a research report on Tuesday, March 19th. Barclays initiated coverage on shares of Privia Health Group in a report on Wednesday, March 6th. They set an “equal weight” rating and a $22.00 target price for the company. Truist Financial dropped their price objective on shares of Privia Health Group from $32.00 to $28.00 and set a “buy” rating for the company in a research note on Thursday, February 29th. Jefferies Financial Group started coverage on Privia Health Group in a research note on Monday, February 26th. They issued a “buy” rating and a $25.00 target price on the stock. Finally, Evercore ISI dropped their price target on Privia Health Group from $26.00 to $25.00 and set an “outperform” rating for the company in a research report on Wednesday, February 28th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, Privia Health Group currently has a consensus rating of “Moderate Buy” and an average target price of $28.18.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.